For example, there are now several examples of highly potent NMT inhibitors against both human and malaria parasite NMTs, but achieving a high level of selectivity has proven challenging to date due to high homology between NMTs at the substrate-binding site (Supplementary Fig. 14c–e). The gene discussed is NMT1; the disease is malaria.